Connor Clark & Lunn Investment Management Ltd. Takes $1.16 Million Position in Insmed, Inc. $INSM

Key Points

• Connor Clark & Lunn Investment Management Ltd. acquired 15,143 shares of Insmed, Inc., valued at approximately $1,155,000, as part of new investments in the first quarter.
• Insmed's recent quarterly earnings showed a loss of ($1.70) earnings per share, which fell short of analysts' expectations of ($1.30).
• Recent analyst upgrades included price target increases by multiple firms, with Mizuho raising their target to $165.00, reinforcing a consensus "Moderate Buy" rating.

Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 15,143 shares of the biopharmaceutical company's stock, valued at approximately $1,155,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Insmed by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock worth $1,393,675,000 after purchasing an additional 49,149 shares during the period. Darwin Global Management Ltd. grew its holdings in Insmed by 23.5% in the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after buying an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Insmed by 1.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock worth $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors grew its holdings in Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after buying an additional 593,206 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Insmed by 19.9% in the 4th quarter. Northern Trust Corp now owns 1,750,642 shares of the biopharmaceutical company's stock worth $120,864,000 after buying an additional 290,678 shares in the last quarter.

Insider Activity at Insmed

In other news, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the sale, the chief financial officer owned 73,505 shares in the company, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $129.50, for a total value of $1,295,000.00. Following the sale, the director owned 274,516 shares of the company's stock, valued at $35,549,822. This trade represents a 3.51% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 539,694 shares of company stock worth $53,144,604. 3.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on INSM. Leerink Partners increased their price objective on Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. Mizuho increased their price objective on Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. Stifel Nicolaus increased their price objective on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Finally, Wells Fargo & Company increased their price objective on Insmed from $130.00 to $140.00 and gave the stock an "overweight" rating in a report on Tuesday, August 12th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Insmed presently has an average rating of "Moderate Buy" and an average target price of $132.57.

Insmed Price Performance

NASDAQ INSM traded up $3.15 on Thursday, reaching $132.60. 2,243,717 shares of the stock traded hands, compared to its average volume of 3,185,723. The firm's fifty day simple moving average is $106.82 and its 200 day simple moving average is $85.31. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The company has a market cap of $28.03 billion, a price-to-earnings ratio of -23.22 and a beta of 0.95. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $132.64.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. As a group, research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.